Vericel (NASDAQ:VCEL) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Vericel (NASDAQ:VCEL) from a sell rating to a hold rating in a research report released on Monday.

VCEL has been the topic of a number of other reports. Truist Financial raised their target price on shares of Vericel from $56.00 to $57.00 and gave the company a buy rating in a research note on Tuesday, July 16th. TD Cowen raised their target price on shares of Vericel from $55.00 to $60.00 and gave the company a buy rating in a research note on Tuesday, August 27th. Stephens raised their target price on shares of Vericel from $56.00 to $58.00 and gave the company an overweight rating in a research note on Friday, August 2nd. BTIG Research lowered their target price on shares of Vericel from $56.00 to $55.00 and set a buy rating on the stock in a research note on Monday, July 15th. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They issued a buy rating and a $57.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $55.75.

Vericel Trading Up 1.6 %

VCEL stock opened at $41.35 on Monday. The firm has a 50 day moving average of $46.75 and a 200-day moving average of $47.29. Vericel has a 12 month low of $30.18 and a 12 month high of $54.10. The firm has a market capitalization of $2.01 billion, a P/E ratio of -4,135.00 and a beta of 1.67.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $52.70 million during the quarter, compared to analyst estimates of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. Vericel’s revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business earned ($0.11) earnings per share. Sell-side analysts predict that Vericel will post 0.12 EPS for the current year.

Insider Activity at Vericel

In related news, insider Sean C. Flynn sold 15,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $52.18, for a total value of $782,700.00. Following the completion of the sale, the insider now directly owns 707 shares in the company, valued at $36,891.26. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $51.40, for a total value of $899,500.00. Following the completion of the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $11,356,161.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean C. Flynn sold 15,000 shares of Vericel stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total value of $782,700.00. Following the completion of the sale, the insider now owns 707 shares of the company’s stock, valued at $36,891.26. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,500 shares of company stock valued at $1,932,200. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC grew its stake in shares of Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares during the last quarter. CWM LLC grew its stake in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 504 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 220 shares during the last quarter. Lazard Asset Management LLC grew its stake in shares of Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,657 shares during the last quarter. Finally, RiverPark Advisors LLC purchased a new stake in shares of Vericel during the first quarter worth about $147,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.